166 related articles for article (PubMed ID: 31629424)
1. Prostate cancer genetic testing: NCCN familial high-risk assessment: breast/ovarian.
Daly MB
Can J Urol; 2019 Oct; 26(5 Suppl 2):29-30. PubMed ID: 31629424
[TBL] [Abstract][Full Text] [Related]
2. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.
Lorenzo Bermejo J; Hemminki K
Ann Oncol; 2004 Dec; 15(12):1834-41. PubMed ID: 15550590
[TBL] [Abstract][Full Text] [Related]
3. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
[TBL] [Abstract][Full Text] [Related]
4. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
[TBL] [Abstract][Full Text] [Related]
5. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
Doren A; Vecchiola A; Aguirre B; Villaseca P
Climacteric; 2018 Dec; 21(6):529-535. PubMed ID: 30295091
[TBL] [Abstract][Full Text] [Related]
6. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Daly MB; Pal T; Berry MP; Buys SS; Dickson P; Domchek SM; Elkhanany A; Friedman S; Goggins M; Hutton ML; ; Karlan BY; Khan S; Klein C; Kohlmann W; ; Kurian AW; Laronga C; Litton JK; Mak JS; ; Menendez CS; Merajver SD; Norquist BS; Offit K; Pederson HJ; Reiser G; ; Senter-Jamieson L; ; Shannon KM; Shatsky R; Visvanathan K; Weitzel JN; Wick MJ; Wisinski KB; Yurgelun MB; Darlow SD; Dwyer MA
J Natl Compr Canc Netw; 2021 Jan; 19(1):77-102. PubMed ID: 33406487
[TBL] [Abstract][Full Text] [Related]
7. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
[TBL] [Abstract][Full Text] [Related]
8. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
Antoniou A; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Loman N; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
Am J Hum Genet; 2003 May; 72(5):1117-30. PubMed ID: 12677558
[TBL] [Abstract][Full Text] [Related]
9. Cancer surveillance behaviors in women presenting for clinical BRCA genetic susceptibility testing.
Loescher LJ; Lim KH; Leitner O; Ray J; D'Souza J; Armstrong CM
Oncol Nurs Forum; 2009 Mar; 36(2):E57-67. PubMed ID: 19273395
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.
Bunnell AE; Garby CA; Pearson EJ; Walker SA; Panos LE; Blum JL
J Genet Couns; 2017 Feb; 26(1):105-112. PubMed ID: 27276934
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Rauh-Adelmann C; Lau KM; Sabeti N; Long JP; Mok SC; Ho SM
Mol Carcinog; 2000 Aug; 28(4):236-46. PubMed ID: 10972993
[TBL] [Abstract][Full Text] [Related]
12. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
Wolff TA; Wilson JE
Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
[No Abstract] [Full Text] [Related]
13. Rate of BRCA mutation in patients tested under NCCN genetic testing criteria.
Beck AC; Yuan H; Liao J; Imperiale P; Shipley K; Erdahl LM; Sugg SL; Weigel RJ; Lizarraga IM
Am J Surg; 2020 Jan; 219(1):145-149. PubMed ID: 31255259
[TBL] [Abstract][Full Text] [Related]
14. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 24366402
[No Abstract] [Full Text] [Related]
15. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
Riahi A; Chabouni-Bouhamed H; Kharrat M
Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients.
Manguoğlu E; Güran S; Yamaç D; Colak T; Simşek M; Baykara M; Akaydın M; Lüleci G
Cancer Genet Cytogenet; 2010 Dec; 203(2):230-7. PubMed ID: 21156238
[TBL] [Abstract][Full Text] [Related]
17. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement.
U.S. Preventive Services Task Force
Ann Intern Med; 2005 Sep; 143(5):355-61. PubMed ID: 16144894
[TBL] [Abstract][Full Text] [Related]
18. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer.
Berliner JL; Fay AM; Cummings SA; Burnett B; Tillmanns T
J Genet Couns; 2013 Apr; 22(2):155-63. PubMed ID: 23188549
[TBL] [Abstract][Full Text] [Related]
19. Mutations of BRCA genes in hereditary breast and ovarian cancer.
Radice P
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):9-12. PubMed ID: 12585647
[TBL] [Abstract][Full Text] [Related]
20. Pros and cons of screening for BRCA mutations.
Howard-McNatt M
N C Med J; 2013; 74(6):489-90. PubMed ID: 24316772
[No Abstract] [Full Text] [Related]
[Next] [New Search]
